On 1/8/24, Pacific Biosciences of Californi (NASDAQ: PACB) stock suffered a major decline of -18.5%, closing at $7.66. Moreover, trading volume in this decline was exceptionally high at 375% of normal. The stock has been extremely weak relative to the market over the last nine months and has declined -26.1% during the last week.
Current PriceTarget Research Rating
PACB is expected to continue to be Value Creation neutral reflecting capital returns that are forecasted to be in line with the cost of capital.
Pacific Biosciences of Californi has a current Value Trend Rating of F (Lowest Rating). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing consistent signals. Pacific Biosciences of Californi has a poor Power Rating of 26 and a very low Appreciation Score of 9, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment